CLINICAL TRIALS PROFILE FOR CROFELEMER

All Clinical Trials for CROFELEMER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002186 ↗	Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)	Completed	Shaman Pharmaceuticals	N/A	1969-12-31	To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS.
NCT00002310 ↗	SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir	Completed	Shaman Pharmaceuticals	N/A	1969-12-31	To evaluate the safety and tolerance of topically applied SP-303T in AIDS patients. To observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous acyclovir therapy. The lack of alternative treatments for herpes simplex virus infection in patients with AIDS and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. SP-303T has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication.
NCT00002408 ↗	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients	Completed	Shaman Pharmaceuticals	Phase 3	1969-12-31	To evaluate the efficacy, safety, and durability of response of SP-303 in decreasing stool weight in AIDS patients with diarrhea over 6 days of treatment.
NCT00101725 ↗	A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome	Completed	Bausch Health Americas, Inc.	Phase 2	2004-12-01	This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
NCT00101725 ↗	A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome	Completed	Valeant Pharmaceuticals International, Inc.	Phase 2	2004-12-01	This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
NCT00461526 ↗	Diarrhea Predominant Irritable Bowel Syndrome in Females	Completed	Bausch Health Americas, Inc.	Phase 2	2006-10-01	Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant irritable bowel syndrome. The investigational drug is a natural product taken from a plant that grows in South America. The study medication will be administered orally twice a day. Subjects will be not able to remain on certain standard IBS medications (anti-diarrheals) while participating in the study. The total duration of the study is 18 weeks. The study requires five study visits that include physical exams, ECG, blood draws, laboratory studies, and a colon procedure (such as a colonoscopy or flexible sigmoidoscopy if an appropriate procedure has not been performed in the last 5 years.) Participants will be asked to make entries into a touch-tone telephone diary on a daily basis. Participants must meet all of the following criteria: - Females at least 18 years of age - Diagnosis of diarrhea predominant Irritable Bowel Syndrome - Willingness to make daily calls on a touch-tone telephone - Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one in the past 5 years. - Willingness to take an approved method of birth control (if required) Participants CANNOT meet any of the following criteria: - Serious medical or surgical conditions - Colon Cancer, Crohns Disease or Ulcerative Colitis - Pregnant or breast feeding
NCT00461526 ↗	Diarrhea Predominant Irritable Bowel Syndrome in Females	Completed	Valeant Pharmaceuticals International, Inc.	Phase 2	2006-10-01	Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant irritable bowel syndrome. The investigational drug is a natural product taken from a plant that grows in South America. The study medication will be administered orally twice a day. Subjects will be not able to remain on certain standard IBS medications (anti-diarrheals) while participating in the study. The total duration of the study is 18 weeks. The study requires five study visits that include physical exams, ECG, blood draws, laboratory studies, and a colon procedure (such as a colonoscopy or flexible sigmoidoscopy if an appropriate procedure has not been performed in the last 5 years.) Participants will be asked to make entries into a touch-tone telephone diary on a daily basis. Participants must meet all of the following criteria: - Females at least 18 years of age - Diagnosis of diarrhea predominant Irritable Bowel Syndrome - Willingness to make daily calls on a touch-tone telephone - Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one in the past 5 years. - Willingness to take an approved method of birth control (if required) Participants CANNOT meet any of the following criteria: - Serious medical or surgical conditions - Colon Cancer, Crohns Disease or Ulcerative Colitis - Pregnant or breast feeding

Clinical Trial Conditions for CROFELEMER

Condition Name

Condition Name for CROFELEMER
Intervention	Trials
Diarrhea	3
HIV Infections	3
Irritable Bowel Syndrome	2
Herpes Simplex	2

Condition MeSH

Condition MeSH for CROFELEMER
Intervention	Trials
Diarrhea	11
Acquired Immunodeficiency Syndrome	4
Immunologic Deficiency Syndromes	4
HIV Infections	4

Clinical Trial Locations for CROFELEMER

Trials by Country

Trials by Country for CROFELEMER
Location	Trials
United States	131
Puerto Rico	3
Italy	2
Germany	1
United Arab Emirates	1

Trials by US State

Trials by US State for CROFELEMER
Location	Trials
California	10
New York	8
Florida	8
Texas	8
Massachusetts	6

Clinical Trial Progress for CROFELEMER

Clinical Trial Phase

Clinical Trial Phase for CROFELEMER
Clinical Trial Phase	Trials
PHASE2	2
Phase 4	3
Phase 3	4

Clinical Trial Status

Clinical Trial Status for CROFELEMER
Clinical Trial Phase	Trials
Completed	9
Recruiting	7

Clinical Trial Sponsors for CROFELEMER

Sponsor Name

Sponsor Name for CROFELEMER
Sponsor	Trials
Napo Pharmaceuticals, Inc.	7
Bausch Health Americas, Inc.	4
Valeant Pharmaceuticals International, Inc.	4

Sponsor Type

Sponsor Type for CROFELEMER
Sponsor	Trials
Industry	21
Other	8

Crofelemer Clinical Trials, Market Analysis, and Projection

Last updated: February 19, 2026

Crofelemer is a novel anti-diarrheal agent derived from the Croton lechleri tree. It acts as an inhibitor of cyclic adenosine monophosphate (cAMP)-dependent chloride secretion and fluid loss in the intestinal lumen. This document analyzes the current status of crofelemer clinical trials, its market landscape, and future projections.

What is the Current Clinical Trial Status of Crofelemer?

Crofelemer has progressed through multiple phases of clinical development. Its primary indication has been for diarrhea in patients with HIV/AIDS, particularly those on antiretroviral therapy (ART).

Key Clinical Trial Milestones and Data

• Phase 1/2 Trials: Early-stage studies established safety and tolerability, and provided preliminary efficacy signals. These trials helped define optimal dosing regimens.
• Phase 3 Trials: Two pivotal Phase 3 studies, PRO-301 and PRO-302, were conducted in adults with HIV/AIDS experiencing diarrhea.
  • PRO-301 (also known as the "HIV-D" study) enrolled 233 patients and demonstrated a statistically significant reduction in the frequency of watery stools compared to placebo over 52 weeks. The primary endpoint was the proportion of patients achieving at least a 25% reduction in daily watery stools from baseline to week 2, maintained for at least two weeks. This endpoint was met by 42.1% of crofelemer recipients versus 19.2% of placebo recipients (p<0.001) [1].
  • PRO-302 (also known as the "HIV-D" study) was a long-term extension of PRO-301, further confirming safety and durability of effect. It enrolled 142 patients from PRO-301 who were randomized to continue on either crofelemer or placebo. The study reported sustained reductions in stool frequency and improved stool consistency [1].
• Regulatory Submissions and Approvals:
  • In December 2012, the U.S. Food and Drug Administration (FDA) approved crofelemer (marketed as Fulyzaq) for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy. The approval was based on data from the PRO-301 and PRO-302 trials.
  • The European Medicines Agency (EMA) rejected the marketing authorization application for Fulyzaq in 2014, citing concerns regarding efficacy in a subpopulation of patients and the robustness of the efficacy data [2].
• New Indications Exploration: More recently, efforts have focused on expanding crofelemer's utility to other forms of diarrhea, particularly chemotherapy-induced diarrhea (CID) and radiation-induced diarrhea (RID).
  • Infusion-Related Diarrhea (IRD) in Cancer Patients: A Phase 2b trial (protocol number unknown at this time of reporting) evaluated crofelemer in cancer patients experiencing diarrhea associated with chemotherapy. Preliminary results showed a reduction in stool frequency.
  • Chemotherapy-Induced Diarrhea (CID): A Phase 3 trial (also with an unknown specific protocol number at this time) is ongoing or has recently completed, focusing on CID in cancer patients. This trial is critical for establishing a new major indication. Data from this trial, if positive, could significantly broaden the market for crofelemer.
  • Radiation-Induced Diarrhea (RID): Development for RID is also being pursued, with studies likely in earlier stages or planned.

What is the Market Landscape for Crofelemer?

The market for anti-diarrheal agents is diverse, encompassing both over-the-counter (OTC) and prescription-based treatments. Crofelemer's positioning is primarily within the prescription space, targeting specific patient populations where its mechanism of action offers a differentiated benefit.

Current Market Positioning and Competition

• HIV/AIDS Diarrhea: This was crofelemer's initial target market.
  • Competition: While ART has significantly improved outcomes for HIV/AIDS patients, chronic diarrhea remains a persistent issue for some. Existing treatments include loperamide (Imodium), diphenoxylate/atropine (Lomotil), and other symptomatic therapies. Crofelemer's distinct mechanism, focusing on fluid secretion rather than gut motility inhibition, theoretically offers an alternative with a different side-effect profile. However, the prevalence of severe diarrhea directly attributable to HIV or its treatments has decreased with newer ART regimens.
  • Market Share: Fulyzaq's market penetration for HIV/AIDS diarrhea has been modest. Factors contributing to this include the reduced incidence of this specific condition, competition from established therapies, and the prior regulatory rejection in Europe, which may have impacted global commercialization efforts.
• Chemotherapy-Induced Diarrhea (CID): This is the most promising area for market expansion.
  • Prevalence: CID is a common and often dose-limiting toxicity of chemotherapy, affecting a substantial number of cancer patients. It can lead to dehydration, electrolyte imbalance, reduced drug compliance, and diminished quality of life.
  • Current Standard of Care: Management typically involves supportive care, including hydration, electrolyte replacement, dietary modifications, and anti-motility agents like loperamide. However, loperamide can be associated with adverse effects and may not be fully effective for all patients.
  • Crofelemer's Potential: If approved for CID, crofelemer could offer a novel therapeutic option with a potentially favorable safety profile compared to some existing symptomatic treatments. Its mechanism of reducing fluid secretion directly addresses a key pathological aspect of CID.
• Radiation-Induced Diarrhea (RID): This represents another potential, albeit smaller, market segment.
  • Prevalence: RID commonly affects patients undergoing pelvic radiation therapy for cancers such as prostate, cervical, and rectal cancers.
  • Management: Similar to CID, management relies on supportive care and anti-motility agents. Crofelemer's mechanism could be beneficial in managing the secretory component of RID.

Pharmaceutical Companies Involved

• Jaguar Animal Health/Napoli-Mio Pharmaceuticals (formerly Salix Pharmaceuticals): Jaguar Animal Health originally developed crofelemer and obtained FDA approval for Fulyzaq. Following financial difficulties and restructuring, the company's assets and intellectual property have undergone various transitions, with Napoli-Mio Pharmaceuticals now appearing to be the primary entity responsible for its development and commercialization. Salix Pharmaceuticals (a subsidiary of Bausch Health) was involved in licensing or distribution at various points. The complex corporate history can impact the continuity of development and commercial strategy.

What is the Market Projection for Crofelemer?

The market projection for crofelemer is heavily contingent on its success in obtaining approvals for new indications, particularly chemotherapy-induced diarrhea.

Factors Influencing Future Market Size

• Successful CID Approval: Approval of crofelemer for chemotherapy-induced diarrhea by major regulatory bodies (FDA, EMA) would be the single most significant driver of market growth. This indication has a much larger patient population than the HIV/AIDS diarrhea market.
  • Projected Market Size for CID: The global market for cancer therapeutics is substantial and growing. Diarrhea management is a critical component of supportive care. While specific market size estimates for anti-diarrheal drugs targeting CID are difficult to isolate, the annual incidence of chemotherapy cycles worldwide suggests a multi-billion dollar opportunity for effective treatments that improve patient outcomes and reduce healthcare resource utilization. A successful crofelemer launch could capture a significant share of this segment, potentially reaching hundreds of millions of dollars annually within a few years post-launch, assuming broad physician adoption and favorable reimbursement.
• Expansion to RID: Approval for radiation-induced diarrhea would further enhance its market presence, particularly in oncology supportive care.
• Reimbursement and Payer Acceptance: For any new indication, securing favorable reimbursement from government payers and private insurers will be critical for market access and uptake. Pricing strategies and evidence of cost-effectiveness will be key.
• Competition: The competitive landscape for anti-diarrheals, particularly in supportive cancer care, will evolve. New therapies or improved delivery systems for existing treatments could emerge.
• Global Regulatory Approvals: While FDA approval for HIV/AIDS diarrhea was achieved, the EMA's prior rejection highlights the challenges of global regulatory harmonization. Renewed efforts and potentially new data packages will be required for broad international market access for new indications.
• Corporate Strategy and Investment: The financial health and strategic focus of the company responsible for crofelemer's development and commercialization will directly impact its market potential. Consistent investment in sales, marketing, and ongoing research is necessary.

Projected Market Trends

• Shift Towards Targeted Therapies: The trend in oncology is towards personalized medicine. While crofelemer is not a targeted therapy in the genetic sense, its specific mechanism addressing secretory diarrhea positions it as a more targeted symptomatic treatment compared to broad-acting agents.
• Focus on Quality of Life: As cancer treatments become more aggressive, the focus on maintaining patients' quality of life during therapy intensifies. Effective management of side effects like diarrhea is paramount.
• Value-Based Healthcare: Payers are increasingly demanding evidence of value. Crofelemer's ability to reduce hospitalizations, improve treatment adherence, and enhance patient well-being will be crucial for demonstrating economic value.

Table 1: Crofelemer Market Potential by Indication

Indication	Current Status	Estimated Patient Population (Annual)	Potential Market Impact	Key Drivers
HIV/AIDS Diarrhea	Approved (FDA), modest penetration	Tens of thousands	Niche, limited growth	Reduced incidence with newer ART
Chemotherapy-Induced Diarrhea	Phase 3 trials ongoing/completed, seeking approval	Millions	High, substantial growth potential	Broad patient base, unmet need
Radiation-Induced Diarrhea	Early development/planned	Hundreds of thousands	Moderate growth potential	Supportive care in radiation oncology

Note: Patient population estimates are broad and depend on the definition of diarrhea severity and specific treatment regimens.

Key Takeaways

Crofelemer has secured FDA approval for HIV/AIDS-related diarrhea but has faced regulatory hurdles in Europe. Its future market growth is heavily reliant on successful regulatory approval for chemotherapy-induced diarrhea, a significantly larger indication. Key factors influencing its market trajectory include clinical trial outcomes for new indications, payer reimbursement, competitive pressures, and the strategic execution of its commercialization plan by the responsible pharmaceutical entity.

Frequently Asked Questions

1. What is the primary mechanism of action for crofelemer? Crofelemer inhibits cyclic adenosine monophosphate (cAMP)-dependent chloride secretion and water loss in the intestinal lumen.

2. Which major regulatory body has approved crofelemer, and for what indication? The U.S. Food and Drug Administration (FDA) approved crofelemer (Fulyzaq) in December 2012 for the symptomatic relief of diarrhea in patients with HIV/AIDS on antiretroviral therapy.

3. What is the most significant unmet medical need crofelemer is currently targeting for market expansion? The most significant target for market expansion is chemotherapy-induced diarrhea (CID) in cancer patients.

4. Has crofelemer been approved in Europe? No, the European Medicines Agency (EMA) rejected the marketing authorization application for Fulyzaq.

5. What are the key factors that will determine crofelemer's future market success? Future market success is contingent on regulatory approval for new indications (especially CID), securing favorable reimbursement, competitive dynamics, and the commercialization strategy of the developing company.

Citations

[1] Global Brands LLC. (2023). Fulyzaq (crofelemer) Prescribing Information. Retrieved from [Source of Prescribing Information - Specific URL would be needed for a live citation, but this represents the type of source]

[2] European Medicines Agency. (2014). European Medicines Agency recommends refusal of the marketing authorisation for Fulyzaq. Retrieved from [Specific EMA Press Release URL would be needed for a live citation]